Amarantus Bioscience Holdings Inc (AMBS)

[breezy1]

Since MANF is protected, I would assume a short version of it is as well. It would be a question for the CEO likely via Twitter.

This story is from 2010 such promise, where is the follow up?
Moving very slowly, my previous post 2012, so in 2014 we are due for some more updates on research outside MJFF organization.

https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=644

INTERIM PROGRESS REPORT

MANF is one of two new molecules (the other is CDNF) currently in pre-clinical development for the treatment of Parkinson's disease. In a recently completed pre-clinical model of Parkinson's disease funded by MJFF, MANF corrected the neurological deficits when it was given immediately after the animals became sick. MANF also corrected the neurological deficits when it was given three weeks after the models became sick. This means that MANF is able to prevent the death of healthy dopaminergic neurons, but also MANF can save dopaminergic neurons that are already dying. How do these results apply to human patients? The results suggest that in patients newly diagnosed with Parkinson's disease MANF might be able to save those dopaminergic neurons that are sick and dying, but not yet dead. These patients will likely get better sooner, and their recovery will also last for a longer time. It is much too soon to predict whether MANF will be able to cure Parkinson's disease. MANF is certainly one of the most promising molecules currently in development to treat this debilitating disease.